8-K: Clorox Reports FY26 Results, Faces Margin Pressure

The Clorox Company announced its fourth quarter and full fiscal year 2026 results, reporting a 2% net sales decrease for Q4 and a 5% decrease for the full year, impacted by ERP transition effects and acquisition costs, while providing a FY27 outlook with expected organic sales growth.

Summary

• The Clorox Company reported its financial results for the fourth quarter and fiscal year ended June 30, 2026.
• Net sales for Q4 FY26 decreased by 2% to $1.95 billion, and for the full fiscal year 2026, net sales decreased by 5% to $6.72 billion.
• Diluted EPS for Q4 FY26 decreased by 50% to $1.34, and for the full fiscal year 2026, it decreased by 26% to $4.81.
• Adjusted EPS for Q4 FY26 decreased by 42% to $1.66, and for the full fiscal year 2026, it decreased by 28% to $5.53.
• Gross margin decreased by 520 basis points in Q4 FY26 to 41.3% and by 290 basis points for the full year to 42.3%.
• The company completed the acquisition of GOJO Industries, Inc. (GOJO) in April 2026.
• The ERP implementation in the U.S. concluded, with significant impacts on shipments and earnings in FY25 and FY26.
• For fiscal year 2027, Clorox expects net sales to increase by 13% to 14% and diluted EPS to be between $5.41 and $5.71.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to slightly negative sentiment due to significant EPS declines and gross margin compression, despite strategic acquisitions and system implementations.

Positives

• Completed the acquisition of GOJO Industries, Inc., strengthening the health and hygiene portfolio which now represents over half of net sales.
• Successfully completed the U.S. ERP implementation, a foundational modernization of systems and processes.
• Invested in innovation, nearly doubling new product introductions across its expanded portfolio in FY26.
• The company expects organic sales growth of 3.5% to 4.5% in fiscal year 2027.
• The company expects diluted EPS to increase by 12% to 19% in fiscal year 2027.
• International net sales increased by 4% in Q4 FY26, with organic sales growing by 1%.

Negatives

• Net sales decreased by 2% in Q4 FY26 and 5% for the full fiscal year 2026.
• Diluted EPS decreased by 50% in Q4 FY26 and 26% for the full fiscal year 2026.
• Adjusted EPS decreased by 42% in Q4 FY26 and 28% for the full fiscal year 2026.
• Gross margin compressed significantly, decreasing by 520 basis points in Q4 FY26 and 290 basis points for the full year.
• Net cash provided by operations decreased by 38% in FY26 compared to FY25.
• Household and Lifestyle segments experienced significant net sales decreases of 18% and 17% respectively in Q4 FY26.

Risks

• Continued cost volatility and a value-seeking consumer are expected in fiscal year 2027.
• Higher-than-normal inflationary headwinds and negative mix are expected to impact gross margin in FY27.
• Integration of GOJO's business presents risks, including realizing anticipated benefits and synergies.
• Increased exposure to customer concentration and consolidation in B2B channels due to the GOJO acquisition.
• Potential for increased regulatory exposure from GOJO's product portfolio subject to FDA oversight.
• Risks related to supply chain issues, product shortages, and disruptions due to expanded supplier networks and single-source suppliers.
• Reliance on information technology systems, including potential security breaches, cyberattacks, or data breaches.
• Intense competition in the company's markets.

Future Outlook

For fiscal year 2027, Clorox anticipates net sales to increase by 13% to 14%, including approximately 9.5 points from the GOJO acquisition. Organic sales are projected to grow 3.5% to 4.5%, benefiting from lapping the ERP-related inventory drawdown. Gross margin is expected to be around 42%, with inflationary headwinds and negative mix offsetting cost savings. Selling and administrative expenses are projected at 16% of net sales, and advertising spending at 10% of net sales. Diluted EPS is forecasted to be between $5.41 and $5.71, representing a 12% to 19% year-over-year increase. Adjusted EPS is expected to be between $5.70 and $6.00, a 3% to 8% increase.

Management Comments

• "Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment."
• "Throughout fiscal year 2026, we strengthened our business despite continued consumer and macroeconomic pressures."
• "We expanded our portfolio through the acquisition of GOJO Industries, completed our U.S. ERP implementation... while advancing our digital capabilities."
• "Together, these actions have strengthened our foundation and position us well to navigate a challenging operating environment as we work to return to organic sales growth."
• "We exited the year with improved execution, a stronger innovation pipeline and a clear plan to deliver superior value across our portfolio, better meeting evolving consumer needs and driving long-term growth."
• "As we begin fiscal year 2027, we expect the operating environment to remain challenging, with continued cost volatility and a value-seeking consumer."
• "We are confident that the investments we've made in our brands, capabilities and products position us to deliver long-term value for shareholders."

Industry Context

StockSavvy.ai notes that Clorox's performance reflects broader consumer staples sector challenges, including inflation, supply chain pressures, and shifts in consumer spending towards value. The acquisition of GOJO positions Clorox to capitalize on the growing health and hygiene market, a trend accelerated by recent global health events.

Comparison to Industry Standards

• The reported gross margin of 41.3% for Q4 FY26 is below the typical margins seen in the consumer staples sector, which often range from the mid-40s to low-50s for well-established companies, indicating pressure from costs and the GOJO inventory step-up.
• The significant year-over-year decline in EPS (50% for Q4, 26% for FY26) is a concern when compared to industry peers who may be showing more stable or modest growth in earnings, even in challenging environments.
• The expected organic sales growth of 3.5%-4.5% for FY27 is modest but aligns with the typical growth rates for mature consumer staples companies, especially when factoring in the benefit of lapping prior year disruptions.
• Competitors like Procter & Gamble and Kimberly-Clark have also faced inflationary pressures, but their ability to pass on costs and manage supply chains effectively will be a key differentiator against Clorox's reported margin compression.

Stakeholder Impact

• Shareholders: The significant decrease in EPS and net income may negatively impact shareholder returns and confidence, although the FY27 outlook suggests a potential recovery.
• Employees: The company's strategic investments and simplified operating structure may lead to changes in operational focus and resource allocation.
• Customers: The company aims to better meet evolving consumer needs through innovation and a strengthened portfolio, potentially leading to improved product offerings.
• Suppliers: Increased reliance on an expanded supplier network due to the GOJO acquisition could introduce new dynamics and potential risks in supply chain management.

Next Steps

• Focus on returning to organic sales growth in fiscal year 2027.
• Continue to execute the company's strategy with discipline.
• Build on the momentum created in FY26.
• Deliver greater superiority across the product portfolio.
• Better meet evolving consumer needs.
• Drive long-term growth.

Key Dates

Recommendation

The company is navigating significant headwinds, including margin compression and EPS declines, largely due to ERP transition impacts and acquisition costs. While the GOJO acquisition and ERP completion are strategic positives for long-term foundation, the immediate financial results are concerning. The FY27 outlook shows expected recovery, but the magnitude of the FY26 decline warrants caution. A 'hold' recommendation reflects the uncertainty and the need to see sustained execution and margin improvement before considering a more positive stance.

Keywords

Clorox, GOJO acquisition, Purell, FY26 results, ERP implementation, organic sales, diluted EPS, gross margin